Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En klinisk fas III-prövning av grupp A och C meningokockpolysackaridvaccin

En randomiserad, dubbelblind, kontrollerad, icke-underlägsenhet fas III-studie av ett grupp A och C meningokockpolysackaridvaccin hos friska barn i åldrarna 2-6 år

This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.

Studieöversikt

Detaljerad beskrivning

This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.

Studietyp

Interventionell

Inskrivning (Faktisk)

1280

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Yunnan
      • Kunming, Yunnan, Kina
        • Yunnan Center for Disease Control and Prevention

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

2 år till 50 år (Barn, Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

  • The First stage study (An early safety assessment study):

  • 18-50 years group:

    • Inclusion Criteria:

      1. Healthy adults aged 18 to 50 years.
      2. Proven legal identity.
      3. Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      5. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
      6. Immunization with any vaccine within 30 days.
      7. Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
      16. Any other situations judged by investigators as not suitable for participating in this study.
  • 7-17 years group:

    • Inclusion Criteria

      1. Healthy volunteer aged 7 to 17 years.
      2. Proven legal identity.
      3. Participants and their legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants and their legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
      6. Immunization with any vaccine within 30 days.
      7. Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Women with positive pregnancy test after menarche.
      16. Any other situations judged by investigators as not suitable for participating in this study.
  • 2-6 years group:

    • Inclusion Criteria

      1. Healthy children aged 2 to 6 years.
      2. Proven legal identity.
      3. Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
      5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      6. They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
      7. Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Any other situations judged by investigators as not suitable for participating in this study.

The Second stage study (A phase III clinical trial )

  • Inclusion Criteria

    1. Healthy children aged 2 to 6 years.
    2. Proven legal identity.
    3. Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
    4. Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
    5. Axillary temperature ≤37.0℃.
  • Exclusion Criteria:

    1. Contraindications for vaccination.
    2. History of allergy to vaccines or drugs.
    3. History of Epidemic Cerebrospinal Meningitis.
    4. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
    5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
    6. They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
    7. Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
    8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
    9. Those who developed acute disease or acute attack of chronic disease.
    10. Surgical removal of spleen or other important organs for any reason.
    11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
    12. Blood products such as immunoglobulin were received within 30 days before vaccination.
    13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
    14. Those who participated in other clinical studies.
    15. Any other situations judged by investigators as not suitable for participating in this study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Experimental Vaccine

One dose of Experimental Group A and C meningococcal polysaccharide vaccine

One dose of Experimental Group A and C meningococcal polysaccharide vaccine

Aktiv komparator: Active Comparator Vaccine

One dose of Control Group A and C meningococcal polysaccharide vaccine

One dose of Control Group A and C meningococcal polysaccharide vaccine

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Seroconversion rate of Group A meningococcal bactericidal antibody
Tidsram: 28 days after vaccination

Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination

28 days after vaccination
Seroconversion rate of Group C meningococcal bactericidal antibody
Tidsram: 28 days after vaccination

Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination

28 days after vaccination

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Adverse reactions/events rate
Tidsram: 7 days after vaccination

Occurence of adverse reactions/events after vaccination

7 days after vaccination
Adverse reactions/events rate
Tidsram: 28 days after vaccination

Occurence of adverse reactions/events after vaccination

28 days after vaccination
Serious adverse events
Tidsram: 6 months after the second vaccination

Occurence of Serious adverse events after vaccination

6 months after the second vaccination
GMT of Group A meningococcal bactericidal antibody
Tidsram: 28 days after the second vaccination

GMT of Group A meningococcal bactericidal antibody at day 28 after the second vaccination

28 days after the second vaccination
GMT of Group C meningococcal bactericidal antibody
Tidsram: 28 days after the second vaccination

GMT of Group C meningococcal bactericidal antibody at day 28 after the second vaccination

28 days after the second vaccination

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
GMT of IgG antibody against Hepatitis A
Tidsram: 28 days after the second vaccination

GMT of IgG antibody against Hepatitis A at day 28 after vaccination

28 days after the second vaccination
Seropositive rate of IgG antibody against Hepatitis A
Tidsram: 28 days after the second vaccination

Seropositive rate of IgG antibody against Hepatitis A at day 28 after vaccination

28 days after the second vaccination

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Yan Zheng, Mater, Yunnan Center for Disease Control and Prevention

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 september 2020

Primärt slutförande (Faktisk)

29 april 2021

Avslutad studie (Faktisk)

26 september 2021

Studieregistreringsdatum

Först inskickad

8 december 2020

Först inskickad som uppfyllde QC-kriterierna

28 december 2020

Första postat (Faktisk)

30 december 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera